Actively Recruiting
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-05-05
165
Participants Needed
2
Research Sites
501 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.
CONDITIONS
Official Title
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must voluntarily agree and sign informed consent.
- Male or female aged 18 to 75 years.
- ECOG performance status of 0 or 1.
- Diagnosed with resectable locally advanced rectal cancer.
- No prior anti-tumor treatment for rectal cancer.
- Life expectancy of at least 2 years.
- Male participants with fertile partners and fertile female participants must use effective contraception from consent until 6 months after last investigational drug or radiotherapy.
- Fertile female participants must have a negative pregnancy test within 7 days before first drug administration and must not be breastfeeding.
You will not qualify if you...
- History of local recurrence of rectal cancer after previous treatment.
- Presence of concurrent colon tumors.
- Initially unresectable colorectal cancer or deemed intolerant to surgery.
- Signs of intestinal obstruction, perforation, or high risk of perforation or bleeding.
- Presence of distant metastases.
- Positive lateral lymph nodes on imaging.
- Previous surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy for tumors.
- Pregnant, breastfeeding, or planning pregnancy during the study.
- Uncontrollable mental illnesses or conditions affecting study completion, including substance abuse or legal detention.
- Any other factors increasing risk or interfering with study participation as judged by the investigators.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022
Actively Recruiting
2
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
Research Team
C
Chuanpei Huang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here